HBC Hofseth Biocare

Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

An Extraordinary General Meeting in Hofseth BioCare ASA will be held at the company's premises at Havnegata 11, 6005 Ålesund, on 11 November 2020 at 13:00 CET.

Considering the travel and meeting recommendations and restrictions currently in place due to the extraordinary situation with the Covid-19 pandemic, all shareholders are encouraged to submit a voting proxy to the chairman of the board in lieu of attending the General Meeting in person.

Please find the notice of the Extraordinary General Meeting attached.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Phone:

E-mail:

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

Attachment

EN
21/10/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUAT...

Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This funding will enable AecorBio to complete the investigational work of its lead peptide candidate FT-002a, in advanced prostate cancer, to enable an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2026. Filing the IND wil...

September 17, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & ...

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®️ addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profi...

September 9, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science...

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn HBC is delighted to announce the appointment of Paul Bruhn as Head of New Business Development. Mr Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the...

September 4, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the same quarter last year. Total operating revenue for the first six months of 2025 was NOK 129.3 million (NOK 132.8 million). EBITDA for the quarter was negative NOK 5.4 million, compared to NOK -2.0 million in Q2 2024. The first six months was negative NOK 25.3 million (NOK-18.2 million) The Operational EBIT...

August 22, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for H...

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolis...

July 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch